Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07667829
Recruiting Not applicable

Vasopressor Agents in Pulmonary Hypertension Crisis

NCT07667829 · tracked via the Priya Life Science China tracker
Sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Started
2026-08-19
Last updated
2026-10-30

Condition(s) studied

Pulmonary Arterial Hypertension (PAH)Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Hypertension, Pulmonary

Investigational drug(s) / intervention(s)

Norepinephrine →Dopamine →Epinephrine →

Norepinephrine: The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.

Dopamine: The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min

Epinephrine: The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (up or down) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min

Study summary

Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age \> 18 years old; 2. Signed informed consent form; 3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH); 4. Presenting with manifestations of pulmonary hypertensive crisis; 5. Receiving both diagnosis and treatment in-hospital; 6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment. Exclusion Criteria: 1. At SCAI stage D or stage E ; 2. Patients who only receive a diagnosis but no treatment in the hospital; 3. Uncontrolled hyperthyroidism; 4. Complicated with angle-closure glaucoma; 5. Hypersensitivity to the study drug; 6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane; 7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide); 8. Pregnancy; 9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.

Primary outcome measure(s)

  • All-cause mortality within 28 days — 28 days after enrolment

Trial sites (3)

FacilityCityRegionStatus
Chinese Academy of Medical Sciences, Fuwai Hospital Beijing Beijing Municipality Recruiting
Guangdong Provincial People's Hospital Guangzhou Guangdong Not Yet Recruiting
Zhongnan Hospital of Wuhan University Wuhan Wuhan Not Yet Recruiting

More China National Center for Cardiovascular Diseases trials in China

rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) Starting soon
Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease Recruiting
An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death Active, not recruiting
The Chinese Hypertrophic Cardiomyopathy Study(CHCS) Recruiting
Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy Recruiting

Other trials for the same condition

Comparison of Sequential to Initial Combination Therapy in PAH Recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support Starting soon
PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial Hypertension Recruiting
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Active, not recruiting
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07667829 on ClinicalTrials.gov ↗ ← All trials in China